A plant species of the family CUCURBITACEAE that is a source of TRICHOSANTHIN (a ribosomal inhibitory protein).
An elevated scar, resembling a KELOID, but which does not spread into surrounding tissues. It is formed by enlargement and overgrowth of cicatricial tissue and regresses spontaneously.
The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.

Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. (1/85)

Dermatopontin is a recently discovered extracellular matrix protein with proteoglycan and cell-binding properties and is assumed to play important roles in cell-matrix interactions and matrix assembly. In this study we examined the expression of dermatopontin mRNA and protein in skin fibroblast cultures from patients with hypertrophic scar and patients with systemic sclerosis. Dermatopontin mRNA and protein levels were reduced in fibroblast cultures from hypertrophic scar lesional skin compared with fibroblasts from normal skin of the same hypertrophic scar patient. Fibroblast cultures from systemic sclerosis patient involved skin also showed significantly reduced expression of dermatopontin compared with normal skin fibroblasts from healthy individuals. We also investigated the effects of cytokines and matrix collagen on dermatopontin expression in normal cultured fibroblasts. Transforming growth factor-beta1 increased dermatopontin mRNA and protein levels, while interleukin-4 reduced dermatopontin expression. Substrate coated with type I collagen reduced dermatopontin mRNA levels, the reduction being more prominent in three-dimensional collagen matrices. Our results suggest that the decreased expression of dermatopontin is associated with the pathogenesis of fibrosis in hypertrophic scar and systemic sclerosis, and that the effect of the cytokines and matrix collagen on dermatopontin may have important implications for skin fibrosis.  (+info)

Expression and role of IL-15 in post-burn hypertrophic scars. (2/85)

Hypertrophic scarring is a skin disorder that occurs after wounding and thermal injury. There is accumulating evidence that immunologic processes such as infiltration of activated T lymphocytes and altered cytokine production may play a role in the formation of hypertrophic scars. Interleukin-15, a cytokine identified as a T cell growth factor, also acts as a chemoattractant for T cells and has pro-inflammatory properties. We investigated the expression and the role of this cytokine in hypertrophic scarring. IL-15 expression was compared in skin biopsies of hypertrophic scars (HS) both in active (AHS) and in remission (RHS) phases, in normotrophic scars (NTS) and in normal skin using reverse transcriptase-polymerase chain reaction and immunohistochemistry. IL-15 expression in HS was significantly higher than in NTS or normal skin. Furthermore, AHS expressed higher levels of IL-15 than RHS. Immunohistologic analysis of AHS samples showed strong IL-15 immunoreactivity in keratinocytes and Langerhans cells in the epidermis and in macrophages, fibroblasts, and dermal dendritic cells in the dermis. High levels of IL-15 expression in AHS correlated with abundant infiltration of activated CD3+ cells. Ex vivo experiments indicate that IL-15 can sustain the proliferative response of T cells derived from AHS but not from RHS and NTS. In addition, IL-15 prevents both cytokine deprivation and activation-induced apoptosis of T cells derived from AHS. Taken together, these results suggest that IL-15 can be involved in the recruitment, proliferation, and apoptosis inhibition of T cells in AHS. The findings that the evolution from an AHS to a RHS is associated with a decrease in IL15 expression, and with a loss of IL-15 responsiveness in ex vivo-cultured T cells, indicate that this cytokine plays an important role in the biology of pathologic scar formation.  (+info)

Mechanical forces induce scar remodeling. Study in non-pressure-treated versus pressure-treated hypertrophic scars. (3/85)

Reparative process of second and third degree burns usually results in hypertrophic scar formation that can be treated by pressure. Although this method is efficient, its mechanisms of action are not known. In this work, we have studied the histological organization of hypertrophic scars submitted to pressure. Skin biopsies were performed 2 to 7 months after the onset of treatment in two adjacent regions of the scar, non-pressure- or pressure-treated and analyzed by immunohistochemistry and transmission electron microscopy for extracellular matrix organization and cellular morphology. In non-pressure-treated regions, fibrillin deposits did not present the classical candelabra-like pattern under epidermis and were reduced in dermis; in pressure-treated regions the amount was increased compared to non-pressure-treated regions but the organization was still disturbed. In non-pressure-treated regions, elastin was present in patch deposits; in pressure-treated regions elastin formed fibers, smaller than in normal dermis. Tenascin was present in the whole dermis in non-pressure-treated regions, whereas in pressure-treated regions it was observed only under epidermis and around vessels, as in normal skin. alpha-Smooth muscle actin-expressing myofibroblasts were absent in normal skin, present in large amounts in non-pressure-treated regions, and almost absent in pressure-treated regions. The disturbed ultrastructural organization of dermal-epidermal junction observed in non-pressure-treated regions disappeared after pressure therapy; typical features of apoptosis in fibroblastic cells and morphological aspects of collagen degradation were observed in pressure-treated regions. Our results show that, in hypertrophic scars, pressure therapy restores in part the extracellular matrix organization observed in normal scar and induces the disappearance of alpha-smooth muscle actin-expressing myofibroblasts, probably by apoptosis. We suggest that the pressure acts by accelerating the remission phase of the postburn reparative process.  (+info)

Severe obstructive sleep apnoea secondary to pressure garments used in the treatment of hypertrophic burn scars. (4/85)

Obstructive sleep apnoea (OSA) secondary to pressure garments used to treat hypertrophic scarring of burns has never been reported. The present study describes two children who presented with OSA following introduction of such garments for management of hypertrophic scars following severe facial and upper body burns. Complex sleep polysomnography confirmed severe OSA with desaturations sufficient to result in physiological dysfunction that significantly improved on removal of the garments. As there is little evidence to suggest that the use of such garments alters the end result, the potentially serious side effect of obstructive sleep apnoea should be considered before their use is advised.  (+info)

Expression of oncoproteins c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor. (5/85)

OBJECTIVE: To explore the characteristics of oncoprotein expression of c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor (bFGF). METHODS: Tissues of hypertrophic scars (n = 8), chronic dermal ulcers (n = 8) and normal skin (n = 5) were taken from 21 patients with burns and chronic dermal ulcers in operation. The ABC immunohistochemical method was used to characterize the gene product expression of c-fos, c-jun and bFGF in the above tissues. RESULTS: In normal skin, both c-fos and c-jun protein expression and bFGF protein expression were observed. The signals of both oncoproteins were localized mainly in subcutaneous fibroblasts, but, positive expression of the bFGF protein was mainly in keratinocytes. In hypertrophic scars, positive expression of both oncoproteins could be found mainly in fibroblasts, but bFGF was mainly in fibroblasts and endothelial cells. In chronic dermal ulcers, endothelial cells, some of inflammatory cells and fibroblasts were positive for both of oncoproteins, but the expression of bFGF was only seen in fibroblasts and endothelial cells. CONCLUSIONS: The results indicate that the interaction between both oncoproteins and bFGF exists, and the regulating action between protooncogenes and bFGF is a major course in wound healing. The different expressions of c-fos and c-jun gene products play an important role in regulate bFGF action, thus affecting wound healing.  (+info)

Alterations in fibroblast alpha1beta1 integrin collagen receptor expression in keloids and hypertrophic scars. (6/85)

Keloids and hypertrophic scars are significant symptomatic clinical problems characterized by excess collagen. Although extensive research has focused on fibroblasts and collagen turnover in these aberrant scars, little work has been done on the expression of integrins (cell membrane structures that link cells to extracellular matrix) within these lesions. Integrin-mediated regulation of collagen synthesis has previously been observed in explanted fibroblasts from normal and fibrotic dermis, and integrin alpha1 knockout mice maintain increased collagen synthesis consistent with a role for alpha1beta1 in providing negative feedback on collagen synthesis. These findings suggested the need to evaluate integrin roles in keloids and hypertrophic scars. In this study we examined integrin expression in keloids (n = 11), hypertrophic scars (n = 5), radiation ulcers (n = 2), and normal skin specimens (n = 8). We used a novel approach to analysis by isolating dermal fibroblasts directly from tissue (without explant culture) and determining surface integrin expression by flow cytometry. We found that keloids and hypertrophic scars have marked alterations in fibroblast integrin expression and contain several distinct populations of fibroblasts. One of these populations expresses high levels of alpha1 integrin, and the proportion of these cells is higher in keloids (63% +/- 3.6% SEM) and hypertrophic scars (45% +/- 2.7% SEM) than in normal skin tissues (28% +/- 4.7% SEM). The different populations of fibroblasts defined by integrin expression merge, however, when the cells are serially cultured, suggesting that there may be aspects of the dermal microenvironment that maintain the integrin phenotypic heterogeneity in dermal fibroblasts.  (+info)

Expression of epidermal growth factor receptor and related phosphorylation proteins in hypertrophic scars and normal skin. (7/85)

OBJECTIVE: To study the potential signal pathway involved in pathogenesis of hypertrophic scar formation. METHODS: The samples of scar were obtained from patients with burn wound scars 6 - 28 months post-burn, while the samples of normal control skin came from the donor site of the same patients. Immunohistochemistry and light microscopy techniques were used to identify the expression of epidermal growth factor receptor (EGFR) and phosphotyrosine proteins (p-Tyr), as well as the phosphorylation of signal transducer and activator of transcription 3 (Stat3) in both hypertrophic scars (n = 6) and normal skin (n = 6). RESULTS: Significant differences were observed in the p-Tyr and EGFR positive expression keratinocytes both in hypertrophic scars and normal skin. The expression of p-Tyr, EGFR and Stat3 protein was greater in hypertrophic scars than in normal skin. However, there was no significant difference in p-Stat3 expression between scar tissues and normal skin. CONCLUSION: Different tyrosine kinase activity occurs in hypertrophic scars and normal cutaneous tissues. Initially, varied expression of EGFR is due to different ligand stimulations. However, phosphotyrosine protein and Stat3 are subsequently activated through phosphorylation. In scar tissues, although EGFR has an intrinsic tyrosine kinase activity when activated by EGFR correlated ligand, phosphorylation of Stat3 showed no significant changes. Therefore, cellular signal pathways are induced by EGFR, which might play a role in hypertrophic scar pathogenesis.  (+info)

Prevention and treatment of excessive dermal scarring. (8/85)

Today, wound management to avoid excessive scar formation is increasingly important, especially in populations with Fitzpatrick 3 or higher skin pigmentation. Medical science and industrial development are devoting more effort toward understanding and offering better therapy to control scars. However, advances in scar management have been hampered by the confusing or ambiguous terminology. There is no consensus on what amount of post-traumatic skin scar formation is "normal" and what should be considered "hypertrophic". In the World Health Organization's ICD-9, there is no diagnostic code for hypertrophic scar--only keloid is listed. Yet, the medical and scientific literature distinguishes them as different conditions. Our experience suggests that the diagnosis of keloid disease is greatly over-rendered. For black patients, an elevated scar seems, by default, diagnosed as keloid by most. This confusion results in inappropriate management of scar formation, and occasionally contributes to decision making related to elective or cosmetic surgery. Given that patients are expecting better outcomes from wound care today than in the past, this review article attempts to capture the essential biological factors related to wound scar production and discusses treatment options and indications used by the authors.  (+info)

Trichosanthes is a genus of plants in the cucumber family (Cucurbitaceae) that includes several species with medicinal uses. One of the most well-known species is Trichosanthes kirilowii, also known as Chinese cucumber or Gua Lou. The dried fruit of this plant has been used in traditional Chinese medicine for centuries to treat various ailments such as lung disorders, fever, and inflammation. It contains various bioactive compounds including trichosanthin, which has been studied for its potential anti-viral, anti-tumor, and immunomodulatory effects. However, it's important to note that the use of Trichosanthes or any other herbal medicine should be done under the guidance of a healthcare professional, as they can interact with other medications and have potential side effects.

A hypertrophic cicatrix is a type of scar that forms when the body overproduces collagen during the healing process. Collagen is a protein that helps to repair and strengthen tissues in the body. However, when too much collagen is produced, it can cause the scar to become thickened, raised, and firm.

Hypertrophic scars are usually red or pink in color and may be itchy or painful. They typically develop within a few weeks of an injury or surgery and can continue to grow for several months before eventually stabilizing. Unlike keloids, which are a more severe type of scar that can grow beyond the boundaries of the original wound, hypertrophic scars do not extend beyond the site of the injury.

While hypertrophic scars can be unsightly and cause discomfort, they are generally not harmful to one's health. Treatment options may include corticosteroid injections, silicone gel sheeting, pressure therapy, or laser surgery to help reduce the size and appearance of the scar. It is important to seek medical advice if you are concerned about a hypertrophic scar or if it is causing significant discomfort or distress.

A cicatrix is a medical term that refers to a scar or the process of scar formation. It is the result of the healing process following damage to body tissues, such as from an injury, wound, or surgery. During the healing process, specialized cells called fibroblasts produce collagen, which helps to reconnect and strengthen the damaged tissue. The resulting scar tissue may have a different texture, color, or appearance compared to the surrounding healthy tissue.

Cicatrix formation is a natural part of the body's healing response, but excessive scarring can sometimes cause functional impairment, pain, or cosmetic concerns. In such cases, various treatments may be used to minimize or improve the appearance of scars, including topical creams, steroid injections, laser therapy, and surgical revision.

... cicatrix, hypertrophic MeSH C17.800.120.425 - keloid MeSH C17.800.120.425.125 - acne keloid MeSH C17.800.174.100 - ...
... hypertrophic lupus erythematosus) Winchester syndrome Abnormalities of dermal fibrous and elastic tissue are caused by problems ... chronic cicatrix keratosis) Clonal seborrheic keratosis Common seborrheic keratosis (basal cell papilloma, solid seborrheic ... idiopathic hypertrophic osteoathorpathy, Touraine-Solente-Gole syndrome) Peeling skin syndrome (acral peeling skin syndrome, ... Hypertrophic scar Immunosuppression-associated Kaposi sarcoma Infantile digital fibromatosis (inclusion body fibromatosis, ...
In reviewing the origin of the terms cicatrix and scar, the term cicatrix is interesting in itself. Originally, it was the ... Hypertrophic scars are more common than keloids. Hypertrophic scars may occur in persons of any age or at any site, and they ... Hypertrophic scars are self-limited; they hypertrophy within the confines of the wound. Initially, hypertrophic scars can be ... encoded search term (Widened and Hypertrophic Scar Healing) and Widened and Hypertrophic Scar Healing What to Read Next on ...
Hypertrophic Cicatrix (Hypertrophic Scar) 08/2014. 1. Anoxia (Hypoxia) 09/2013. 1. Dislocations 07/2013. ...
"Cicatrix, Hypertrophic/SU" OR "Cicatrix, Hypertrophic/TH" OR "Cicatrix, Hypertrophic/DT" OR ("Hypertrophic Cicatrices" OR " ... "Hypertrophic Cicatrices" OR "Hypertrophic Cicatrix" OR "Hypertrophic Scar" OR "Hypertrophic Scars" OR Keloid OR keloids OR ... "Cicatrix, Hypertrophic/SU" OR MH:"Cicatrix, Hypertrophic/TH" OR MH:"Cicatrix, Hypertrophic/DT")). Estratégia de busca (Pubmed) ... "Hypertrophic Cicatrix" OR "Hypertrophic Scar" OR "Hypertrophic Scars" OR Keloid OR keloids OR "Hypertrophic keloid" OR " ...
Scar, scarring (see also Cicatrix) 709.2. *. cheloid 701.4. *. hypertrophic 701.4. *. keloid 701.4 ... Other hypertrophic and atrophic conditions of skin 701- ...
... cicatrix, hypertrophic MeSH C17.800.120.425 - keloid MeSH C17.800.120.425.125 - acne keloid MeSH C17.800.174.100 - ...
Cicatrix, Hypertrophic 1 0 Infertility, Female 1 0 Intracranial Arteriovenous Malformations 1 0 ...
Search for : Burn units; Burns; Pediatric intensive care units; Hypertrophic cicatrix; Cicatrix; Plastic surgery ...
Keywords: Umbilicus; Abdominoplasty; Patient satisfaction; Cicatrix, hypertrophic; Abdomen. RESUMO. INTRODUÇÃO: O abdome é um ... Two cases of dehiscence, four cases of hypertrophic scar, two cases of stenosis, and one case of umbilical necrosis were ... Skin-reducing mastectomy using inferior pedicle dermal fat flaps in immediate reconstruction of medium and large hypertrophic ...
CICATRIX, HYPERTROPHIC is also available; do not confuse entry term SCARRING with scarification (scratching open the surface of ... Cicatrix - Preferred Concept UI. M0004472. Scope note. The fibrous tissue that replaces normal tissue during the process of ...
Hypertrophic Cicatrix Medicine & Life Sciences 25% * Keloid Medicine & Life Sciences 24% * Thoracotomy Medicine & Life Sciences ... Although the TAC approach offers a potential cosmetic benefit in patients with a history of keloid or hypertrophic scar ... Although the TAC approach offers a potential cosmetic benefit in patients with a history of keloid or hypertrophic scar ... Although the TAC approach offers a potential cosmetic benefit in patients with a history of keloid or hypertrophic scar ...
Cicatrix, Hypertrophic. Pathways for HYI Antibody (NBP3-06115AF594). View related products by pathway. ...
It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding ... The cicatrix can be either hypertrophic (raised) or atrophic (depressed), depending on the severity of the original wound.. The ... Cicatrix is a term used to describe the scar tissue that forms after an injury or surgery. It is made up of collagen fibers and ... Hypertrophic scars are typically red and raised, while atrophic scars are depressed and may be less noticeable.. While the ...
It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding ...
Reduce hypertrophic scars, recent and old scars, burn marks, acne, stretch marks, and keloids with the Cicatrix Scar Reduc... ...
Cicatrix - Appearance is flat or slightly raised with a pink or reddish color, although it may also be paler or darker than ... Hypertrophic - Appearance is raised and firm, and it may feel painful or restrict movement. ...
Cicatrix, Hypertrophic. Keloid. Tissue Adhesions. Ads by Google. Enter your search terms. ...
Keloid Hypertrophic scar 701.5 Other abnormal granulation tissue Excessive granulation 701.8 Other hypertrophic and atrophic ... tonsil Cicatrix of tonsil (and adenoid) 474.9 Unspecified Disease (chronic) of tonsils (and adenoids) 475 Peritonsillar abscess ... Hypertrophic obstructive cardiomyopathy Hypertrophic subaortic stenosis 425.2 Obscure cardiomyopathy of Africa Beckers disease ... Hypertrophic elongation of cervix 622.7 Mucous polyp of cervix Polyp NOS of cervix Excludes: adenomatous polyp of cervix (219.0 ...
There were 79 patients at the initial stage of scar formation, 102 at the hypertrophic stage, and 43 at the atrophic stage. (1 ... Key words】Cicatrix; Ultrasonography; High-frequency ultrasound; Pathology; Masson staining; Vancouver scar scale; Scar ... Methods The clinical data of patients with the initial stage of scar formation after burn trauma (,1 month), hypertrophic scar ... Conclusion 20MHz high-frequency ultrasound is more accurate than VSS in the assessment of thickness of hypertrophic scar, and ...
Hypertrophic Scar see Scars * Hypopigmentation see Skin Pigmentation Disorders * Impetigo * Infections, Fungal see Fungal ... Cicatrix see Scars * Colorado Tick Fever see Tick Bites * Contact Dermatitis see Rashes ...
Black People , Cicatrix, Hypertrophic/diagnosis , Cicatrix, Hypertrophic/therapy , Cote d'Ivoire , Keloid , Mali ... Contexte : les cicatrices chéloïdiennes sont fréquentes chez le sujet noir africain et particulièrement en Côte dIvoire. La ... Aspects thérapeutiques des cicatrices chéloidiennes au centre de dermatologie du centre hospitalier et universitaire de ... Objectif: Evaluer la prise en charge des cicatrices chéloïdiennes en vue dune codification. Matériels et méthodes :Cette étude ...
Cicatrix Disfigurement of skin due to scar Fibrosis of skin NOS Scar NOS Code Type-2 Excludes: Type-2 Excludes Type-2 Excludes ... Hypertrophic scar - instead, use code L91.0 Keloid scar - instead, use code L91.0 ...
El objetivo de este trabajo es analizar la evidencia acerca del uso del láser de CO2 en cicatrices secundarias a quemaduras. ... One of the most frequent complications in major burns is hypertrophic scarring. There are multiple treatments that are applied ... Respecto a la evidencia analizada, el uso de láser CO2 en cicatrices postquemaduras, parece ser prometedor y seguro, sin ...
However, no single therapy provides optimal results to eliminate hypertrophic scar formation. For most people in the world, ... However, no single therapy provides optimal results to eliminate hypertrophic scar formation. For most people in the world, ... However, no single therapy provides optimal results to eliminate hypertrophic scar formation. For most people in the world, ... However, no single therapy provides optimal results to eliminate hypertrophic scar formation. For most people in the world, ...
Cicatrix Publishing (CP) (1) * Cicerone Journal (1) * Circa: a Literary Review (CP) (1) ... Hypertrophic Literary (CP) (1) * Hypnopomp Magazine (1) * Idle Ink (1) * IHRAF Publishes (1) ...
Cicatrix Publishing (CP) (1) * Cicerone Journal (1) * Circa: a Literary Review (CP) (1) ... Hypertrophic Literary (CP) (1) * Hypnopomp Magazine (1) * Idle Ink (1) * IHRAF Publishes (1) ...
With hypertrophic scars, there is concern that the incisions will not gain access to the blood supply. Minimum depth incisions ... "cicatrix," which means "scar resulting from the formation and contraction of fibrous tissue." (1) Historically, dermatologists ... The thickness of the scalp in areas of scarring can vary significantly depending whether the scar is hypertrophic or atrophic. ... One must also differentiate simple hypertrophic scars from true keloid scar (see Chapter 14A) as transplanting into true keloid ...
Hypertrophic variant is extremely itchy and is resistant to treatment.[14]. Erosive VVLP (EVVLP) is the most common form, ... Cicatrices or strictures and stenosis, when present, require surgical intervention after the resolution of inflammation. ... Hypertrophic LP shows pronounced irregular acanthosis. Erosive LP shows epidermal erosion with underlying inflammation and ... This is a lesser known entity also known as hypertrophic vulvitis, chronic edema of the vulva and Melkersson-Rosenthal vulvitis ...
  • Widened scars can be easily differentiated from hypertrophic and keloid scars based on findings from a physical examination. (medscape.com)
  • Clinically, keloids can be differentiated from hypertrophic scars because they grow outside the confines of the original scar. (medscape.com)
  • Under light microscopy, hypertrophic scars and keloids are indistinguishable. (medscape.com)
  • [ 40 ] Keloids contain thick collagen fibers with increased epidermal hyaluronic content, whereas hypertrophic scars exhibit nodular structures with fine collagen fibers and increased levels of alpha smooth muscle actin. (medscape.com)
  • The collagen in both keloids and hypertrophic scars is organized in discrete nodules, frequently obliterating the rete pegs in the papillary dermis of the lesions. (medscape.com)
  • While collagen in normal dermis is arranged in discrete fascicles separated by considerable interstitial space, collagen nodules in keloids and in hypertrophic scars appear avascular and unidirectional and are aligned in a highly stressed configuration. (medscape.com)
  • Ogawa R, Akaishi S, Kuribayashi S, Miyashita T. Keloids and Hypertrophic Scars Can Now Be Cured Completely: Recent Progress in Our Understanding of the Pathogenesis of Keloids and Hypertrophic Scars and the Most Promising Current Therapeutic Strategy. (medscape.com)
  • Treatment of hypertrophic and keloid scars with SILASTIC Gel Sheeting. (medscape.com)
  • Kwon SY, Park SD, Park K. Comparative effect of topical silicone gel and topical tretinoin cream for the prevention of hypertrophic scar and keloid formation and the improvement of scars. (medscape.com)
  • Intralesional injection of keloids and hypertrophic scars with the Dermo-Jet. (medscape.com)
  • Keloids and hypertrophic scars are the result of abnormalities in the wound healing process. (blogspot.com)
  • By contrast, hypertrophic scars extend only to the wound edge, frequently regress, and are unlikely to recur. (blogspot.com)
  • Hypertrophic scars are elevated lesions that do not reach past a wound's boundaries, while widened scars are wounds that separate during the healing process, usually in response to tension perpendicular to the wound edges. (medscape.com)
  • Examples of disfiguring scars include keloids, widened scars, and hypertrophic scars. (medscape.com)
  • Both keloid and hypertrophic scars are wounds that heal overzealously above the skin surface. (medscape.com)
  • Although both can be red and raised, keloids continue to grow and hypertrophic scars tend to regress over time. (medscape.com)
  • Triamcinolone injections have been the standard treatment to induce flattening, fading, and decreased symptomatology of hypertrophic scars. (medscape.com)
  • Because abnormal scar formation is unique to humans, animal model research contributions have been limited to our understanding and the treatment of keloids and hypertrophic scars. (medscape.com)
  • Background Hypertrophic scars (HScs) are inelastic scars that can cause functional loss and disfigurement. (tmu.edu.tw)
  • Yang, JY & Huang, CY 2010, ' The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: A new strategy for the treatment of hypertrophic scars ', Dermatologic Surgery , vol. 36, no. 12, pp. 1942-1949. (tmu.edu.tw)
  • Trofolastin Scar Reducer is used for the treatment of hypertrophic and keloid scars. (bioax.es)
  • Trofolastin Scar Reducer is a great periareolar treatment for hypertrophic and keloid scars. (bioax.es)
  • The difference between a keloid and a hypertrophic scar is that a keloid continues to enlarge beyond the original size and shape of the wound, while a hypertrophic scar enlarges within the confines of the original wound. (medscape.com)
  • The treatment of hypertrophic scar, keloid and scar contracture by triamcinolone acetonide. (medscape.com)
  • These effects are expected to expedite the wound healing process, reducing contracture and preventing hypertrophic scar and keloid formation. (koreamed.org)
  • 13. [Clinical effects of free transplantation of expanded thoracodorsal artery perforator flaps in reconstructing cervical cicatrix contracture deformity after burns]. (nih.gov)
  • Carswell L, Borger J. Hypertrophic Scarring Keloids. (medscape.com)
  • Studies have demonstrated 80-100% improvement in hypertrophic scar formation. (medscape.com)
  • However, in patients with a history of keloid or hypertrophic scar formation, the cosmetic result may sometimes be unsatisfactory. (elsevierpure.com)
  • Although the TAC approach offers a potential cosmetic benefit in patients with a history of keloid or hypertrophic scar formation, a more generalized use cannot be recommended based on current evidence. (elsevierpure.com)
  • Topical silicone gel for the prevention and treatment of hypertrophic scar. (medscape.com)
  • In reviewing the origin of the terms cicatrix and scar, the term cicatrix is interesting in itself. (medscape.com)
  • Even white spots, leukonychia, so often seen on toenails, were included under the term cicatrix. (medscape.com)
  • Cohen IK, Keiser HR, Sjoerdsma A. Collagen synthesis in human keloid and hypertrophic scar. (medscape.com)
  • Additionally, the Cicatrix cream results in to skin reconstruction, thereby improving skin health. (com.bd)
  • Take a coin-sized amount of the Cicatrix cream in your hands and apply to the face. (com.bd)